Conditions: Myasthenia Gravis
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 14
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.

Detailed description:

Arms:
arm 1: eculizumab arm 2: Placebo

Interventions: intervention 1: eculizumab intervention 2: Placebo
Intervention descriptions: intervention 1: eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses intervention 2: Placebo IV weekly for 4 doses then every two weeks for 7 doses

Protocol document: